Scientists have recommended to investigate graphene and graphene base compounds for their potential uses in a variety of fields, such as biomedicine and drug release. A PEGylated and functionalized magnetic graphene oxide (MG–NH₂–PEG) complex was used herein as a nanocarrier of Doxorubicin, a cancer chemotherapy drug. First, graphene oxide was synthesized by modified Hummer’s method and then functionalized with amine groups (G–NH₂). Afterwards, solvothermal of Fe₃O₄ magnetic nanoparticles on G–NH₂ to prepare magnetic graphene oxide (MGO) modified by MG–NH₂ via covalent bindings for the synthesis of MG–NH₂–PEG. Doxorubicin (DOX) was loaded onto MG–NH₂–PEG at pH 7 by the use of π–π interactions, yielding a highly significant value of DOX's loading efficiency along with its loading content. In vitro cytotoxicity tests on MCF-7 cells line were carried out for MG–NH₂–PEG: DOX according to the drug loading and release characteristics. The results of standard MTT assay for the toxicity determination of both synthetic nanocomposites and the drug revealed over 85% of surviving cells after 48 h, with a cellular uptake of > 80%, suggesting a satisfactory outcome on the non-toxicity of the nanocomposite. It can, therefore, be concluded that MG–NH₂–PEG showed to be an effective drug carrier in cancer chemotherapy drug delivery through loading the above drugs of low medicinal properties with individual dependency on pH levels. Furthermore, MG–NH₂–PEG represent strong optical absorbance from the visible to the near-infrared (NIR) region, and can be utilized for localized photothermal ablation of cancer cells guided by the magnetic field.

High yield recombinant protein production is highly desirable for biotechnological purposes. In the design of recombinant expression conditions, a number of essential central elements such as expression strain, type of medium, bioprocess optimization, and mathematical modeling should be considered. Well-designed industrial scale production of one recombinant protein with optimized influential parameters and yield can address the cost and production reproducibility issues. In the present study, statistical experimental design methodology was used to investigate the effect of fermentation conditions (dissolved oxygen, IPTG, and temperature) on rPDT production by Escherichia coli. rPDT is a recombinant fusion protein consisting of three different protein domains including the N-terminal 179 amino acid fragment of the S1 subunit of pertussis toxin, the full-length genetically detoxified diphtheria toxin (CRM197), and the 50 kDa tetanus toxin fragment C. A 15 Box–Behnken design augmented with center points revealed that IPTG and DO at the center point and low temperature will result in high yield. The optimal condition for rPDT production were found to be 100 µM IPTG, DO 30% and temperature 20 °C.

Objective: In this study, novel graphene oxide (GO)-based nanocomposites are presented. In fact, we have tried to replace the carboxyl groups on the surface of GO with amine groups to allow the biocompatible poly(ethylene glycol) bis(carboxymethyl) ether (average Mn 600) polymer to bond through an amide bond. Materials and methods: The synthesis was conducted accurately according to final characterization experiments (Raman, X-ray diffraction [XRD], atomic force microscopy [AFM], X-ray photoelectron spectroscopy [XPS], thermogravimetric analysis [TGA], etc). The antimicrobial property of this nanocomposite was examined in Escherichia coli (ATCC 25922) as Gram-negative and Staphylococcus aureus (ATCC 25923) as Gram-positive bacterial species. Besides, curcumin (CUR) was added to the produced nanocomposite both as a promising anticancer drug and an antioxidant, the toxicity of which was then assessed on cellular-based HepG2 and pC12. Results: An intense increase in toxicity was detected by MTT assay. Conclusion: It can mainly be concluded that the nanocomposite synthesized in this study is capable of delivering drugs with antibacterial properties.